Found 356 oncology trials
A listing of oncology medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
The main purpose of this study is to test the efficacy and safety (benefit and risks) of itolizumab, when added to corticosteroids, as treatment for aGVHD.
This study evaluates the trabectedin and irinotecan in the treatment of Ewings sarcoma, with a EWS-FLI1 mutation. Patients will also receive an infusion of 18F-FLT in combination with a Positron Emission Tomography (PET) scan to help evaluate the effect of treatment.
The purpose of this study is to evaluate how well the study drug (Navitoclax) works in combination with ruxolitinib when compared to best available therapy in subjects with Relapsed/Refractory Myelofibrosis.
-For US: Aged 10 to 25 years on the day of inclusion ("10-25 years" means from the day of the 10th birthday to the day before the 26th birthday) For EU: Aged 42 to 89 days or 12 to 18 months or 10 to 50 years on the day of …
The research study is being conducted to investigate the potential benefits of Enzastaurin in combination with temozolomide and radiation therapy in newly-diagnosed glioblastoma patients with the Denovo Genomic Marker1 (DGM1).
Normal 0 false false false EN-US X-NONE X-NONE This research study is a phase 3, double-blind clinical trial to assess the efficacy of Agios versus placebo in subjects with residual or recurrent Grade 2 oligodendroglioma and astrocytoma with an IDH1 or IDH2 mutation who have undergone surgery as their only …
A first-in-man Phase 1, non-randomized, multi-centre, open-label clinical trial designed to investigate the safety, tolerability, pharmacokinetics of [111In]-FPI-1547 Injection and [225Ac]-FPI-1434 Injection and to establish the maximum tolerated dose of a single [225Ac]-FPI-1434 Injection in patients with solid tumours with demonstrated tumour uptake of [111In]-FPI-1547. Includes a sub-study of FPI-1175 …
The study is investigating efficacy, safety and tolerability of DNA-damage Response Agents (or Combinations), in participants with advanced/metastatic solid malignancies whose tumours contain molecular alterations.
You are being asked to participate in the Radiation Oncology Registry. Participation in this study requires no additional obligations on your part; your participation means you are granting permission for your doctors to extract information from your medical chart and use this data for research purposes. Should any findings from …
The overall prevalence of Ovarian Cancer in the United States according to the US SEER Registry is 182,710 women. Ovarian cancer also has the highest mortality rate of the gynecological cancers. The overall five-year survival rate is 45% and for Stages III and IV it is only 20-25%. The majority …
